OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Wainberg on the Need for Chemotherapy-Free Options in CRC

February 18th 2021

Zev A. Wainberg, MD, discusses the need to develop chemotherapy-free options in colorectal cancer.

Dr. Shadman on the Potential Utility of LOXO-305 in CLL

February 18th 2021

Mazyar Shadman, MD, discusses the potential utility of LOXO-305 in chronic lymphocytic leukemia.

Dr. Dean on the Potential Role of Consolidative CAR T-Cell Therapy in MCL

February 18th 2021

Robert M. Dean, MD, discusses the potential role for consolidative CAR T-cell therapy in mantle cell lymphoma.

Dr. Ruan on the Future of Lenalidomide/Rituximab in MCL

February 17th 2021

Jia Ruan, MD, PhD, discusses the future evaluation of lenalidomide plus rituximab in mantle cell lymphoma.

Dr. Davies on Selecting Between Combination Regimens in BRAF-Mutant Melanoma

February 17th 2021

Michael A. Davies, MD, PhD, discusses factors to consider when selecting between combination regimens in BRAF-mutant melanoma.

Dr. Nichols on the Prognosis of Patients With VHL Disease

February 17th 2021

Kim E. Nichols, MD, discusses the prognosis of patients with von Hippel-Lindau disease.

Dr. Grothey on the Rationale to Evaluate Patritumab Deruxtecan in HER3+ CRC

February 16th 2021

Axel Grothey, MD, discusses the rationale to evaluate patritumab deruxtecan in HER3-positive colorectal cancer.

Dr. Lee on the Potential Utility of Ibrutinib/Cirmtuzumab in MCL

February 16th 2021

Hun Ju Lee, MD, discusses the potential utility of ibrutinib in combination with cirmtuzumab in mantle cell lymphoma.

Dr. Hari on Mitigating Selinexor-Related Toxicities in Multiple Myeloma

February 16th 2021

Parameswaran Hari, MD, MRCP, discusses mitigating selinexor-related toxicities in relapsed/refractory multiple myeloma.

Dr. Raghav on the Utility of Chemotherapy-Free Intervals in CRC

February 15th 2021

Kanwal Raghav, MBBS, MD, discusses the utility of chemotherapy-free intervals in colorectal cancer.

Dr. Mead on the Clinical Significance of the MURANO Trial in CLL

February 15th 2021

Monica D. Mead, MD, discusses the clinical significance of the phase 3 MURANO trial in chronic lymphocytic leukemia.

Dr. Jain on the Efficacy of Ibrutinib/Rituximab in MCL

February 15th 2021

Preetesh Jain, MD, PhD, discusses the efficacy of ibrutinib plus rituximab in mantle cell lymphoma.

Off Our Chests: John Marshall, MD, and Liza Marshall Recount Her TNBC Journey

February 15th 2021

John Marshall, MD, and his wife, Liza, recount the challenging journey of Liza's triple-negative breast cancer (TNBC) diagnosis and how John's career as a gastrointestinal oncologist played into the caregiving process. The interview comes ahead of the release of their book, Off Our Chests, which goes further in depth with their experience.

Dr. Weiss on the FDA Approval of Trilaciclib in Small Cell Lung Cancer

February 12th 2021

Jared Weiss, MD, discusses the FDA approval of trilaciclib in small cell lung cancer.

Dr. Ruan on the Long-Term Benefits of Lenalidomide/Rituximab in MCL

February 12th 2021

Jia Ruan, MD, PhD, discusses the long-term benefits of lenalidomide plus rituximab in mantle cell lymphoma.

Dr. Schiller on the Potential Utility of Asciminib in CML

February 12th 2021

Gary J. Schiller, MD, discusses the potential utility of asciminib in chronic myeloid leukemia.

Dr. Coveler on the Rationale to Evaluate NUC-3373 in Metastatic CRC

February 12th 2021

Andrew Coveler, MD, discusses the rationale to evaluate NUC-3373 in metastatic colorectal cancer.

Dr. Grothey on Potential Combinations With Trastuzumab Deruxtecan in GI Malignancies

February 11th 2021

Axel Grothey, MD, discusses potential combination strategies with fam-trastuzumab deruxtecan-nxki in gastrointestinal malignancies.

Dr. Brahmer on Emerging Targeted Therapies in EGFR Exon 20–Mutated Lung Cancer

February 10th 2021

Julie R. Brahmer, MD, discusses emerging targeted therapies for patients with lung cancer who harbor EGFR exon 20 insertion mutations.

Dr. Schmidt on the Clinical Implications of AMG 420 in Multiple Myeloma

February 8th 2021

Timothy M. Schmidt, MD, discusses the clinical implications of AMG 420 in multiple myeloma.